Masimo softFlow™

Masimo softFlow™

 
TUTTO
PUBBLICATI
QUALIFICA
Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD.

Bräunlich et al. Int J Chron Obstruct Pulmon Dis 2019;(14):1411-1421.

Reductions in dead space ventilation with nasal high flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls.

Biselli et al. Eur Respir J 2018;51:1702251.

Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study.

Biselli et al. J Appl Physiol (1985). 2017;122(1):82-88.

Nasal highflow improves ventilation in patients with COPD.

Bräunlich J et al.
Int J Chron Obstruct Pulmon Dis. 2016;(11):1077-1085.

Nasal High-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report.

Bräunlich J et al.
Multidiscip Respir Med. 2015;10(1):27. 

Nasal high-flow in acute hypercapnic exacerbation of COPD

Bräunlich J, Wirtz H.
Int J Chron Obstruct Pulmon Dis. 2018;13:3895-3897.
doi:10.2147/COPD.S185001

Nasal highflow eliminates CO2 from lower airways.

Bräunlich J, Goldner F, Wirtz H.
Respir Physiol Neurobiol. 2017;242:86-88. doi:10.1016/j.resp.2017.03.012

Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients.

Bräunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H.
Respiration. 2013;85(4):319-325. doi:10.1159/000342027

Mechanisms of nasal high flow on ventilation during wakefulness and sleep.

Mündel T, Feng S, Tatkov S, Schneider H.. J Appl Physiol (1985). 2013;114(8):1058-1065.
doi:10.1152/japplphysiol.01308.2012

Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD.

Bräunlich et al. Int J Chron Obstruct Pulmon Dis 2019;(14):1411-1421.

Reductions in dead space ventilation with nasal high flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls.

Biselli et al. Eur Respir J 2018;51:1702251.

Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study.

Biselli et al. J Appl Physiol (1985). 2017;122(1):82-88.

Nasal highflow improves ventilation in patients with COPD.

Bräunlich J et al.
Int J Chron Obstruct Pulmon Dis. 2016;(11):1077-1085.

Nasal High-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report.

Bräunlich J et al.
Multidiscip Respir Med. 2015;10(1):27. 

Nasal high-flow in acute hypercapnic exacerbation of COPD

Bräunlich J, Wirtz H.
Int J Chron Obstruct Pulmon Dis. 2018;13:3895-3897.
doi:10.2147/COPD.S185001

Nasal highflow eliminates CO2 from lower airways.

Bräunlich J, Goldner F, Wirtz H.
Respir Physiol Neurobiol. 2017;242:86-88. doi:10.1016/j.resp.2017.03.012

Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients.

Bräunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H.
Respiration. 2013;85(4):319-325. doi:10.1159/000342027

Mechanisms of nasal high flow on ventilation during wakefulness and sleep.

Mündel T, Feng S, Tatkov S, Schneider H.. J Appl Physiol (1985). 2013;114(8):1058-1065.
doi:10.1152/japplphysiol.01308.2012

Descrizione dei simboli delle evidenze cliniche:

Indica un documento PDF

Indica un abstract o una presentazione

Indica un articolo di una rivista sottoposta a peer review

Le pubblicazioni o abstract duplicati sono esclusi

This section is intended to provide access to clinical studies conducted using Masimo noninvasive technologies, parameters, and products. We cannot guarantee that all published clinical studies, abstracts and research are listed here. To view individual clinical studies please click on the appropriate tab

Some uses of the manufacturer’s devices described in the information may note have been approved or cleared by the FDA. See manufacturer labeling for the indications in the product’s cleared indications for use statement.

L'evidenza clinica è fornita per illustrare le prestazioni e l'accuratezza delle tecnologie Masimo. La legge federale limita la vendita dei dispositivi Masimo per scopi medici da parte di un medico o su sua prescrizione.

PLCO-004774/PLMM-11836B-0421